Amgen Inc reports results for the quarter ended September 30 - Earnings Summary

What happened

Amgen reported adjusted earnings of $6.45 per share for the quarter ended September 30, compared with $5.64 a year earlier and analysts’ $5.79 average estimate. Revenue rose 8.5% to $10.37 billion, above the $10.07 billion expected; reported earnings per share were $7.08 and net income was $3.86 billion.

Confirmed

Global impact / market context

Earnings and revenue above analyst expectations indicate stronger quarterly results than forecasts, which may support confidence in Amgen’s ability to generate sales and profit. However, four analysts cut earnings estimates in the past 30 days, suggesting that expectations are not uniformly improving.

Analyst inference

Amgen shares had already risen 10.4% this quarter and 42.2% year to date, while the average analyst rating was hold. The median 12-month price target of $410 was 13.5% below the last closing price of $465.45.

Confirmed

What to watch

1. Compare upcoming earnings with analyst estimates to see whether the recent revenue growth and earnings beat continue, since sustained results could strengthen confidence in future sales. Analyst inference
2. Track analyst estimate revisions and the balance of buy, hold, and sell ratings; further downgrades could signal weaker expected profit despite the latest reported beat. Analyst inference
3. Watch whether the share price moves toward or away from the stated $410 median 12-month target, which was 13.5% below the last closing price. Analyst inference

Evidence

• Original source link unavailable